Aquestive Therapeutics Inc’s recently made public that its Chief Operating Officer Jung Cassie unloaded Company’s shares for reported $214.0 on Nov 26 ’24. In the deal valued at $4.87 per share,44 shares were sold. As a result of this transaction, Jung Cassie now holds 0 shares worth roughly $0.0.
Then, Schobel Alexander Mark sold 50,000 shares, generating $300,000 in total proceeds. Upon selling the shares at $6.00, the Chief Innovation/Tech Officer now owns 984,476 shares.
Before that, Schobel Alexander Mark sold 25,000 shares. Aquestive Therapeutics Inc shares valued at $129,685 were divested by the Chief Innovation/Tech Officer at a price of $5.19 per share. As a result of the transaction, Schobel Alexander Mark now holds 1,040,371 shares, worth roughly $3.35 million.
Cantor Fitzgerald initiated its Aquestive Therapeutics Inc [AQST] rating to an Overweight in a research note published on December 17, 2024; the price target was $17. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early May with a ‘”an Outperform”‘ rating. Piper Sandler began covering AQST with “an Overweight” recommendation on April 11, 2024. Raymond James started covering the stock on March 28, 2024. It rated AQST as “an Outperform”.
Price Performance Review of AQST
On Tuesday, Aquestive Therapeutics Inc [NASDAQ:AQST] saw its stock fall -2.42% to $3.22. Over the last five days, the stock has lost -8.52%. Aquestive Therapeutics Inc shares have fallen nearly -9.55% since the year began. Nevertheless, the stocks have risen 37.61% over the past one year. While a 52-week high of $6.23 was reached on 01/02/25, a 52-week low of $2.24 was recorded on 01/07/25. SMA at 50 days reached $4.40, while 200 days put it at $3.95.
Levels Of Support And Resistance For AQST Stock
The 24-hour chart illustrates a support level at 3.13, which if violated will result in even more drops to 3.04. On the upside, there is a resistance level at 3.37. A further resistance level may holdings at 3.51. The Relative Strength Index (RSI) on the 14-day chart is 31.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.86%. Stochastics %K at 16.63% indicates the stock is a buying.
How much short interest is there in Aquestive Therapeutics Inc?
A steep rise in short interest was recorded in Aquestive Therapeutics Inc stocks on 2024-12-13, dropping by -0.31 million shares to a total of 9.65 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 9.97 million shares. There was a decline of -3.22%, which implies that there is a negative sentiment for the stock.
